Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Eletriptan hydrobromide
Drug ID BADD_D00756
Description Eletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches.
Indications and Usage For the acute treatment of migraine with or without aura in adults.
Marketing Status approved; investigational
ATC Code N02CC06
DrugBank ID DB00216
KEGG ID D01973
MeSH ID C115647
PubChem ID 656631
TTD Drug ID D02DMQ
NDC Product Code 65015-719; 65162-042; 59651-104; 27241-040; 59651-105; 55700-756; 59762-2322; 10829-0558; 48087-0090; 0378-4288; 65162-043; 68382-922; 70771-1107; 48087-0102; 63126-904; 65977-0059; 68382-923; 71335-1830; 59762-2321; 0049-2330; 0378-4287; 70771-1108; 0093-8311; 63629-8320; 0049-2340; 10829-0557; 59651-101; 0093-8310; 27241-039
UNII M41W832TA3
Synonyms eletriptan | (R)-3-((1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole | UK 166,044 | UK-166044 | UK 166044 | UK-166,044 | Relpax | UK-116044-04 | UK-116,044-04 | eletriptan hydrobromide | (R)-3-((1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole monohydrobromide | 3-(1-methyl-2-pyrrolidinylmethyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole hydrobromide
Chemical Information
Molecular Formula C22H27BrN2O2S
CAS Registry Number 177834-92-3
SMILES CN1CCCC1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4.Br
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Oesophagitis07.08.05.001--
Osteoarthritis15.01.04.001---
Otitis media04.05.01.001; 11.01.05.004--
Palpitations02.11.04.012--
Paraesthesia17.02.06.005; 23.03.03.094--
Paralysis17.01.04.004---
Parosmia17.04.04.002; 22.04.03.007---
Peripheral vascular disorder24.03.01.003---
Pharyngitis07.05.07.004; 11.01.13.003; 22.07.03.004--
Photophobia06.01.01.004; 17.17.02.006--
Pollakiuria20.02.02.007--
Polyuria20.02.03.002---
Pruritus23.03.12.001--
Psoriasis10.02.01.036; 23.03.14.002---
Purpura01.01.04.003; 23.06.01.004; 24.07.06.005--
Pyrexia08.05.02.003--
Rash23.03.13.001---
Rash maculo-papular23.03.13.004--
Renal pain20.02.03.003---
Respiratory disorder22.02.07.002---
Rheumatoid arthritis10.04.06.001; 15.01.03.001---
Rhinitis11.01.13.004; 22.07.03.006--
Salivary hypersecretion07.06.01.009---
Seizure17.12.03.001--
Shock24.06.02.002---
Sinusitis11.01.13.005; 22.07.03.007--
Skin discolouration23.03.03.005---
Skin disorder23.03.03.007---
Skin hypertrophy23.01.04.002---
Sleep disorder19.02.04.001---
The 5th Page    First    Pre   5 6 7    Next   Last    Total 7 Pages